Press Releases Year None20212020201920182017 June 16, 2021 SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma PDF Version June 15, 2021 SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference PDF Version June 7, 2021 SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma PDF Version June 1, 2021 SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference PDF Version May 14, 2021 SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit PDF Version May 10, 2021 SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development PDF Version May 6, 2021 SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights PDF Version May 6, 2021 SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio PDF Version April 12, 2021 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version April 1, 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last »
June 16, 2021 SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma PDF Version
June 15, 2021 SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference PDF Version
June 7, 2021 SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
June 1, 2021 SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference PDF Version
May 14, 2021 SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit PDF Version
May 10, 2021 SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development PDF Version
May 6, 2021 SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights PDF Version
May 6, 2021 SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio PDF Version
April 12, 2021 Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
April 1, 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
